Viridian Therapeutics target price raised to $34 from $31 by Wells Fargo
VRDN•Wells Fargo raised its target price for Viridian Therapeutics to $34 from $31.
Related News
Brookfield Business Holdings Corp Q3 revenue USD 1,400 million
BBUC•
Mizuho cuts HubSpot target price to $240 from $260
HUBS•
Strategic Education Q3 revenue rises 1.6%, slightly misses estimates
STRA•
Evommune hosts webcast to discuss EVO570 licensing deal
EVMN•
FS KKR Capital Q3 net investment income per share rises
FSK•